• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Jeuveau (PrabotulinumtoxinA-xvfs) for Glabellar Lines

Article

What you need to know about the new botulinum toxin product.

Jeuveau Product Image

Jeuveau (PrabotulinumtoxinA-xvfs, Evolus™ )

Indications: temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugatory and/or procerus muscle activity in adult patients

Dosage: 0.1 mL by intramuscular injection into each of five sites on the face. 

Contraindications:

  • Hypersensitivity to botulinum toxin preparation or any components of the formulation 

  • Infection at the injection site

Click here for more prescribing information

Related Content
NDA for Investigational Schizophrenia Treatment Submitted to FDA

NDA for Investigational Schizophrenia Treatment Submitted to FDA

October 2nd 2023
Article

The NDA was submitted for investigational muscarinic antipsychotic, KarXT (xanomeline-trospium), which functions as a dual M1/M4 muscarinic acetylcholine receptor agonist within the central nervous system.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

First Anti-Inflammatory Drug for Cardiovascular Disease Approved by FDA

First Anti-Inflammatory Drug for Cardiovascular Disease Approved by FDA

June 21st 2023
Article

Lodoco (colchicine) approval was based on a clinical trial with 5,522 patients with chronic coronary disease, which was published in Circulation in February 2022.

FDA Approves Sotagliflozin For Heart Failure Across Full Range of LVEF

FDA Approves Sotagliflozin For Heart Failure Across Full Range of LVEF

May 30th 2023
Article

The medication is broadly approved for heart failure with preserved or reduced ejection fraction.

FDA Approves First Oral Treatment for Patients With Moderate to Severe Crohn's Disease

FDA Approves First Oral Treatment for Patients With Moderate to Severe Crohn's Disease

May 22nd 2023
Article

The approval of Rinvoq (upadacitinib) was based on the results of three clinical trials: two induction therapy studies and one maintenance study.

FDA Approves Two Medications for Treatment of Schizophrenia 

FDA Approves Two Medications for Treatment of Schizophrenia 

May 2nd 2023
Article

Otsuka America Pharmaceutical and Lundbeck’s Alify Asimtufii (aripiprazole) also was approved for maintenance monotherapy treatment of bipolar I disorder in adults.

© 2023 MJH Life Sciences

All rights reserved.